Macitentan (ACT-064992), a Tissue-Targeting Endothelin Receptor Antagonist, Enhances Therapeutic Efficacy of Paclitaxel by Modulating Survival Pathways in Orthotopic Models of Metastatic Human Ovarian Cancer

Potential treatments for ovarian cancers that have become resistant to standard chemotherapies include modulators of tumor cell survival, such as endothelin receptor (ETR) antagonist. We investigated the therapeutic efficacy of the dual ETR antagonist, macitentan, on human ovarian cancer cells, SKOV...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Kim, Sun-Jin, Kim, Jang Seong, Kim, Seung Wook, Brantley, Emily, Yun, Seok Joong, He, Junqin, Maya, Marva, Zhang, Fahao, Wu, Qiuyu, Lehembre, François, Regenass, Urs, Fidler, Isaiah J
פורמט: Artigo
שפה:Inglês
יצא לאור: Neoplasia Press Inc. 2011
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3033595/
https://ncbi.nlm.nih.gov/pubmed/21403842
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים